Current | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Knut and Alice Wallenberg Foundation Subscribes To Celera Discovery System

Rockville, MD - February 11, 2002

Celera Genomics (NYSE:CRA), an Applera Corporation business, announced today it signed a multi-year agreement with the Knut and Alice Wallenberg Foundation in Sweden, allowing academic researchers in Sweden access to Celera’s database products. Subscribers will have access to Celera's database information and research tools through the Celera Discovery System™. The subscriptions will be administered through the Karolinska Institutet, Sweden’s largest center for medical training and research, which is also a subscriber to Celera’s databases. Financial terms of the agreement were not disclosed.

The Celera Discovery System is an integrated, web-based platform that enables users to leverage Celera’s computational tools, super-computing power, and genomic and biological data to advance the discovery process for researchers worldwide.

About the Knut and Alice Wallenberg Foundation
The Knut and Alice Wallenberg Foundation, based in Sweden, was founded in 1917. Its purpose is to promote scientific research and education. The Foundation fulfills this goal by awarding grants supporting major investments in scientific equipment and major research programs.

About Applera Corporation and Celera Genomics
Applera Corporation comprises two operating groups. The Celera Genomics Group, headquartered in Rockville, MD, is engaged principally in integrating advanced technologies to create therapeutic discovery and development capabilities for internal use and for its customers and collaborators. Celera’s businesses are its online information business and its therapeutics discovery business. The online information business is a leading provider of information based on the human genome and other biological and medical information. Through the therapeutic discovery business, Celera intends to leverage its genomic and proteomic capabilities to identify drug targets and diagnostic marker candidates, and to discover novel therapeutic candidates. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2001. Celera Diagnostics, a joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of novel diagnostics tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923. Information about Celera is available on the World Wide Web at www.celera.com.


Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.